Results 51 to 60 of about 4,421 (195)

The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design

BMC Endocrine Disorders, 2019
Background Hypoglycaemia, especially nocturnal, remains the main limiting factor of achieving good glycaemic control in type 1 diabetes. The effect of first generation long-acting insulin analogues in reducing nocturnal hypoglycaemia is well documented ...
Rikke Mette Agesen, Amra Ciric Alibegovic, Henrik Ullits Andersen, Henning Beck-Nielsen, Peter Gustenhoff, Troels Krarup Hansen, Christoffer Hedetoft, Tonny Jensen, Claus Bogh Juhl, Susanne Søgaard Lerche, Kirsten Nørgaard, Hans-Henrik Parving, Lise Tarnow, Birger Thorsteinsson, Ulrik Pedersen-Bjergaard   +14 more
doaj   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9849-9860, November 2026.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. [PDF]

, 2017
BACKGROUND: Degludec is an ultralong-acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-to-day variability in the glucose-lowering effect and ...
Kajsa Kvist, Moses, A, Pratley, RE, Marso S. P., Lange M., Skibsted, Simon, Zinman B., Buse, John B., Zinman, B, Neil R. Poulter, Kvist, K, Buse, JB, Mcguire D. K., Haahr, P-M, Brown-Frandsen, Kirstine, Brown-Frandsen K., Pieber, TR, Maranghi M., Alan Moses, John B. Buse, Bucciarelli, L., Kvist K., Darren K. McGuire, Poul-Martin Haahr, Emerson S. S., Marso, SP, Brown-Frandsen, K, Buse J. B., McGuire, DK, Buscemi S, Poulter, NR, Lange, M, Simon Skibsted, Skibsted, Simone, DEVOTE Study Group, Mcguire, Darren K., Scott S. Emerson, Pieber T. R., Moses, Alan, Skibsted S., Marso, Stiven P., Lange, Martin, Skibsted, S, Pieber, Thomas R., Kvist, Kajsa, Zinman, Bernard, Bernard Zinman, Martin Lange, Pratley R. E., Moses A., Marso, Steven P., Pratley, Richard E., Haahr, Poul-Martin, Poulter, Neil R., Richard E. Pratley, Steven P. Marso, Poulter N. R., Emerson, Scott S., Emerson, SS, Thomas R. Pieber, Haahr P. -M., Kirstine Brown-Frandsen   +61 more
core   +1 more source

Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit [PDF]

Insulin degludec is a long-acting basal insulin analog that is used as a single daily injection in people living with type 2 diabetes (T2DM) or in combination with rapid-acting analogs in basal-bolus regimens in people living with T2DM or type 1 diabetes
Steve Bain
core   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

Degludec: the new ultra-long insulin analogue [PDF]

Diabetology & Metabolic Syndrome, 2015
The development of extended-action insulin analogues was motivated by the unfavorable pharmacokinetic (PK) profile of the conventional long-acting insulin formulations, generally associated with marked inter and intra patient variability and site- and dose-dependent effect variation.
Tambascia, Marcos Antonio, Eliaschewitz, Freddy Goldberg   +1 more
openaire   +2 more sources

Efficacy and safety of insulin degludec in renal transplant recipients with pre-existing diabetes

Endocrine and Metabolic Science, 2021
Introduction: Glycemic control is important in renal transplant receptions with diabetes. In the early post-transplant period, recovering renal function and concomitant steroids and immunosuppressants increase the risk of dysglycemia which adversely ...
Debmalya Sanyal, Soumyabrata Roy Chaudhuri, Anirban Majumder   +2 more
doaj   +1 more source

Efficacy and safety of insulin glargine 300 units/mL vs insulin degludec in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis

Frontiers in Endocrinology
BackgroundUltra-long-acting insulin analogs [insulin degludec (IDeg) and insulin glargine 300 units/mL (IGla-300)] offer a longer duration of action with less risk of hypoglycemia compared to other long-acting insulins.
Eman N. Alhmoud, Mohamed Omar Saad, Nabil Elhadi Omar, Nabil Elhadi Omar   +3 more
doaj   +1 more source

Impact of Semaglutide, Liraglutide and Tirzepatide on Cardiometabolic Outcomes: A Comparative Narrative Review

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
The comparative pharmacology and cardiometabolic outcomes of semaglutide, liraglutide and tirzepatide, integrating evidence from major clinical trial programs and meta‐analyses. ABSTRACT Background Cardiometabolic disorders such as type 2 diabetes mellitus (T2DM), obesity and cardiovascular disease (CVD) remain major global health challenges.
Hiba Bawadi, Haya Abuhijleh, Mamon Nofal, Zain Z. Zakaria, Maha Al‐Asmakh   +4 more
wiley   +1 more source

Degludec is superior to glargine in terms of daily glycemic variability in people with type 1 diabetes mellitus [PDF]

, 2016
To investigate the differences in glycemic variability between the long-acting insulins glargine and degludec using continuous glucose monitoring, we conducted an open-label, multicenter, prospective, observational study that enrolled 21 participants ...
Kameda, Reina, Nakamura, Akinobu, Fujiwara, Yutaka, Atsumi, Tatsuya, Miyoshi, Hideaki, Kameda, Hiraku, Yamamoto, Chiho, Nomoto, Hiroshi, Ichiyama, Mei   +8 more
core   +1 more source